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Animal models for the assessment of novel
vascular conduits
Michael J. Byrom, MBChB,a,b,c Paul G. Bannon, PhD,a,c,d Geoffrey H. White, FRACS,c,d and
Martin K. C. Ng, PhD,b,c,d Sydney, New South Wales, Australia
The development of an ideal small-diameter conduit for use in vascular bypass surgery has yet to be achieved. The ongoing
innovation in biomaterial design generates novel conduits that require preclinical assessment in vivo, and a number of
animal models have been used for this purpose. This article examines the rationale behind animal models used in the
assessment of small-diameter vascular conduits encompassing the commonly used species: baboons, sheep, pigs, dogs,
rabbits, and rodents. Studies on the comparative hematology for these species relative to humans are summarized, and the
hydrodynamic values for common implant locations are also compared. The large- and small-animal models are then
explored, highlighting the characteristics of each that determine their relative utility in the assessment of vascular
conduits. Where possible, the performance of expanded polytetrafluoroethylene is given in each animal and in each
location to allow direct comparisons between species. New challenges in animal modeling are outlined for the assessment
of tissue-engineered graft designs. Finally, recommendations are given for the selection of animal models for the
assessment of future vascular conduits. ( J Vasc Surg 2010;52:176-95.)
Clinical Relevance: The limitations of autologous arterial and venous segments used in vascular surgery drives the
development of novel vascular conduits which ultimately require assessment in vivo. The abundance of articles
proclaiming successful development of new conduits contrasts starkly with the handful of candidates reaching clinical
trials, a discrepancy due at least in part to a lack of standardised approach to the selection and utilisation of appropriate
animal models. This review seeks to provide for the first time a broad comparison of the pertinent variables determining
the utility of species used for vascular conduit assessment, relevant to researchers and to clinicians evaluating reports of
novel conduit development.Animal models are used to simulate human anatomy,
physiology, and pathologic processes, with extrapolation of
findings to human medicine. Animals have been used for
this purpose since at least the second century, when the
Greek physician Galen (130-200) began his anatomic ex-
periments on the circulation, later correctly described as a
result of further animal research by William Harvey (1578-
1658), and the use of animals has since continued as an
important component of surgical research.1
The development of conduits for use in vascular bypass
surgery has a much more recent history. The use of autolo-
gous (from the same individual) vein for arterial reconstruc-
tion was described in 1906, but it was not until 1949 that
autologous saphenous vein was first used as a femoropopliteal
bypass graft. Frozen and formalin-preserved arterial allografts
(from the same species) were described in 1908, but the utility
of allograft vessel transplants has been limited by thrombosis
and aneurysmal degeneration.2 Bovine arterial xenografts
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176(from a different species) were first implanted in 1962 and
human umbilical vein allografts in 1974,3 but it is polymer
prosthetics, such as polyethylene terephthalate/Dacron and
expanded polytetrafluoroethylene (ePTFE), that remain the
recommended alternatives in peripheral vascular bypass sur-
gery when an autologous vessel is not available.4,5 Prosthetic
vascular conduits were first introduced in 1952 in the form of
porous cloth tubes,2 but the arrival of knitted and woven
Dacron conduits in 1957 changed the management of occlu-
sive vascular disease.6 PTFE was unsuccessfully trialed as a
textile prosthesis before ePTFE was introduced to peripheral
vascular surgery in 1972. Other fields of vascular bypass sur-
gery share an even shorter history of conduit development.
For hemodialysis access surgery, the autologous subcutaneous
arteriovenous fistula first reported in 1966 remains the best
method for provision of long-term vascular access, whereas
ePTFE is the most commonly used graft material for bridge
fistulas.7 Coronary artery bypass grafting surgery began with
the internal thoracic artery as a bypass graft in 1964 and
reversed saphenous vein in 1967,8 and these remain the pri-
mary conduits used due to the rapid failure of ePTFE in this
location.9
The ideal vascular conduit remains the Holy Grail of
vascular surgery,10,11 and the ongoing development of novel
conduits reflects the limitations of autologous vessels as well as
the inadequacies of currently available small-diameter vascular
synthetics. Autologous saphenous vein is unsuitable in up to
one-third of patients presenting with arterial disease of the
lower extremity due to small vein size, varicosities, anatomic
variation, previous removal, or other abnormalities,12 and
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spite normal preoperative quality assessment.13 Vein quality is
an important factor in the later development of graft steno-
sis,14,15 and even if good-quality vein is available, vein harvest
is time-consuming and is amajor contributor to postoperative
morbidity (leg edema and wound complications) that occurs
in 20% to 30% of infrainguinal bypass surgery patients.16
Synthetic vascular conduits work well for large-diameter,
high-flow, low-resistance applications such as aortic re-
placement and aortoiliofemoral grafting, where Dacron
conduits crimped and sealed during the manufacturing
process remain the material of choice.4 ePTFE has become
favored for medium-diameter (6-9-mm) situations where
autologous veins are unavailable or unsuitable,3,4 but for
small-diameter applications (6 mm), such as the infra-
genicular and coronary vessels, the use of synthetic con-
duits has produced disappointing patency rates, and an
ideal vascular graft for these situations is lacking.10,11
The continuing innovation in vascular biomaterial de-
sign aims to overcome these inadequacies and in the pro-
cess generates novel conduits that ultimately require assess-
ment in vivo. Evaluation of new conduits in preclinical
animal studies is required to assess the capacity of the
prosthesis to maintain physiologic function in the circula-
tory system and to determine the response of both the host
and the prosthesis to implantation.17 It is also a require-
ment for regulatory approval, as outlined in published
standards for graft manufacturers recognized by the United
States (U.S.) Food and Drug Administration.17,18
In addition to describing appropriate in vitro testing
methods, these standards lay out the requirements for acqui-
sition of data relating to the preoperative, operative, and
postoperative periods of in vivo preclinical studies. Such data
include the preoperative health status of the animal, implant-
ing surgeon and method, medications given and methods of
assessment used, adverse events, and the details of animal
termination and specimen explant. Although not specifying
whichmodel should be used for any particular prosthesis, they
state that the intended diameter and length of conduit along
with the intended clinical application and the biologic charac-
teristics of the animal should be considered in the selection of
the animal model. These animal experiments precede initial
clinical evaluation studies that establish the short-term safety
and efficacy before general marketing.17
The endeavor to develop an ideal vascular conduit has
so far spanned more than half a century, accumulating a
wealth of published literature and covering a multitude of
species, implant locations, and assessment techniques. This
review provides a comprehensive summary of the compar-
ative hematology between species, comparison of known
values for hydrodynamic measures relevant to vascular con-
duit assessment, and an analysis of the commonly used
animal models, detailing the advantages and disadvantages
for each. Where possible, a direct comparison between
species is given, especially regarding the performance of
ePTFE, because this remains the most widely used control
material in the evaluation of novel vascular prosthetics. The
current era of tissue-engineered vascular grafts brings newchallenges in animal modeling and a discussion of these is
provided. Finally, recommendations are given for the de-
sign of future in vivo assessments. The scope of this review
should prove useful to clinicians seeking knowledgeable
assessment of reports of conduit development as well as to
researchers in the field of vascular biomaterial design.
SEARCH METHODS
An electronic literature search of the U.S. National
Library of Medicine public domain database (MEDLINE)
was performed for articles published from 1950 to present
using the following keywords: animal models, blood vessel
prosthesis, polytetrafluoroethylene, tissue engineering, vascu-
lar surgical procedures, peripheral vascular diseases, papio,
swine, sheep, dogs, rabbits, and rodentia. The references of
the retrieved articles were also manually searched for any
additional relevant articles. These articles were supple-
mented with textbooks of vascular surgery, biomaterials
science, animal models, and veterinary biology.
CONSIDERATIONS IN THE SELECTION OF AN
ANIMAL MODEL
Minimally acceptable criteria for the expected perfor-
mance and methods of evaluation of arterial prostheses were
first proposed in 199319 andwere soon followed by published
standards.20,21 Desirable characteristics of arterial prostheses
proposed at that time remain important today and include
sterility, consistency, reasonable cost, low porosity, good han-
dling (suturability, conformability, and kink resistance), infec-
tion resistance, strength, and durability. An ideal prosthesis
would also demonstrate biomechanical properties that match
those of the target artery and exhibit a thrombosis-resistant
surface hospitable to endothelialization.19
No ideal animal model exists for the assessment of novel
conduits against all of these performance criteria, but a num-
ber ofmodels performwell for specific purposes.19 This reality
is reflected in the number of animal species andmethods of in
vivo assessment that have been used. A summary of animal
models commonly used in the assessment of vascular conduits
is given in Table I for large animals and Table II for small
animals. Other species used to test vascular grafts include
guinea pigs, hamsters, goats, macaques, and vervet mon-
keys.22-26
A number of considerations should be made when
determining an appropriate animal model. This decision
includes not only the animal species but also the anasto-
motic site, caliber and length of prosthesis, and duration of
implantation. Cost, availability, ease of handling during
examinations, response to anesthesia and surgery, and arte-
rial size and flow at sites of conduit implantation are often
used to guide animal selection; however, of primary impor-
tance is the need to select an animal model that correctly
simulates the relevant aspect of human physiology, and
species differences must be considered.
For the chosen animal, decisions regarding conduit im-
plantation should be made with the particular objective of
testing in mind. For example, short-term implantation of
short prostheses in high-flow locations (eg, 4-cm carotid
ac arte
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but might satisfy other objectives such as safety.19 Prostheses
intended for coronary grafting are best assessed in that posi-
tion due to differences in hemodynamics, graft flow, kinking,
and anastomotic conditions compared with peripheral arterial
locations.27 Conduit caliber is a major determinant of graft
patency and depends on native vessel diameter, the type of
anastomosis (end-to-end or end-to-side), and the required
flow rate through the graft. Small calibers result in high
resistance and consequently low blood flow, whereas larger
calibers lead to low wall shear stress, greater pseudointima
thickness, and more anastomotic intimal hyperplasia (IH),
Table I. Large-animal models for the assessment of vascu
Species Site Size (cm, d
Ex vivo conduit
Baboon FA-FV 0.4  NR6
Sheep CA-CA 0.5  438
Dog FA-FV 0.3  1118
In vivo patch
Sheep CA 0.8  5 cm
Dog CAFA NR186
In vivo conduit
Baboon CA 0.4  5-78
Ao-IA 0.4  5,61
FA 0.4  8.29
Sheep CA 0.4  4,11
FA 0.4  4,12
AV CA-JV 0.6
Other Ao 0.7  3
Pig AV FA-FV 0.4
Other SA NR 
Dog CA 0.3  4,19
Ao 0.6  5,19
Ao-IA 0.4  5,19
AV CA-JV 0.6
Other FA 0.4  1
In vivo other
Sheep Aoa,201
Dog SC implant202
Ao, Aorta;AV, arteriovenous graft;CA, carotid artery; FA, femoral artery; F
artery (pig); SC, subcutaneous; SVC, superior vena cava.
aMaterial suspended inside bare stent.
Table II. Small-animal models for the assessment of vascu
Species Site Size (cm, diameter 
In vivo conduit
Rabbit CA 0.15  1,78 0.15 
Ao 0.2/0.3  1,136 0.4
Ao-IA 0.5  438
FA 0.1  1,144 0.15 
Rat Ao 0.1  1,163 0.1  1
0.15  NR,152 0
Other FA 0.1  1,157 FA-
Mouse Ao 0.07-0.13  1165
In vivo other
Rat IP implant 0.5  0.5131
SC implant 0.15  1.2159
Ao, Aorta; CA, carotid artery; FA, femoral artery; NR, not reported; IA, iliwith both situations leading to reduced patency.28 If anasto-motic IH is the focus of the study, a larger graft/native vessel
diameter ratio may be required to simulate the shear stress
conditions of clinical bypass grafts.29
The choice of model is also influenced by the methods
used to measure outcomes and determine significance.
Aortic interposition grafting generally precludes serial ul-
trasound assessment of patency or morphology, necessitating
postmortem evaluation unless other techniques are available
(eg, computed tomography angiography). Implantation of
single conduits prevents paired-site evaluation with a suitable
control, in contrast with bilateral graft placement (eg carotid
or femoral interposition or bypass). Placement of the control
nduits
er  length)
7-990
 4-5,26 0.4  5/10,111 0.5  5,36 0.6  10,187 0.6  11.5113
 5/10,111 0.5  NR,122 0.6  4-5121
-15,188 CA-JV 0.6  11-14118
9
5,130 CA-JV 0.5  7,129 CA-JV 0.6  15128
3 SVC 0.4  1040
 6,191 0.45  6192 (NR)193
 6,195 0.6  6-8,196 0.8  12,180 0.8  30131
 10-12,198 0.5  NR133
,196 FA-FV 0.6  30199
CA-Ao 0.6  45,132 CA-Ao 0.8  7041
oral vein; IA, iliac artery; JV, jugular vein;NR, not reported; SA, saphenous
onduits
th)
0.2  1,142 0.2  1.5,140 0.2  2,141 0.4  3-4,148 0.5  2149
.4,137 0.4  2.4,139 0.4  4-539
0.15  2143
.13  1,161 0.13  1,155 0.15  1,150 0.15  2/10,151
NR,176 0.2  1.3,154 0.3  1149
1  6,156 CA 0.4  1158
ry; IP, intraperitoneal; SC, subcutaneous.lar co
iamet
2
5
116
9
0.4 
3
4 0.4
0 0.4
 10
-418
 6.
3.5,12
0 0.4
4 0.6
7 0.5
 10
2,200
V, femlar c
leng
2,203
 2
1,145
,153 0
.15 
FA 0.conduit in the same animal reduces the effect of interindi-
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platelet aggregation in dogs, and allows paired tests of signif-
icance, reducing the number of subjects required.30 The
choice of control conduit is also important, and new prosthe-
ses should be assessed in comparison with an accepted cur-
rently used alternative, usually ePTFE for smaller conduits due
to difficulties using animal vein.19
Technical considerations include the effects of flexion
and tension. Grafts placed over a flexion crease are known
to exhibit reduced patency, but carotid implants may also
be affected by considerable flexion if sufficiently long.30 Of
48 ePTFE conduits 4-mm in diameter and 5-cm in length
implanted in dogs for 3 months, kinking was noted in 50%
of femoral grafts and also in 17% of carotid grafts.31 Kink-
ing due to excessive length may be avoided by implanting
conduits under mild tension similar to native vessels. In situ
vessels are under longitudinal tension that changes with age
and location: excised arteries retract 22% to 39% in patients
aged 11 to 20 years and 13% to 25% in those aged 36 to 52
years, with retraction increasing in more peripheral loca-
tions.32 Moderate tension after implantation does not af-
fect patency, but in very small arteries excessive tension
leads to increased suture hole bleeding, reduced native
vessel diameter, and reduced patency once the elastic re-
serve of the vessel is exceeded.33,34 Increased tension is
normalized within 7 days of surgery by wall tissue remod-
eling, but these processes are unable to correct for tension
below physiologic levels due to excessive conduit length.35
Although often not reported, the postoperative mortality
of species after the implantation of vascular conduits may be
significant, depending on the nature of the procedure and
experience of the institution. Sheep, for instance, pose a diffi-
culty during endotracheal intubation because the cranial lobe
of the right lung arises directly from the trachea rather than
from the right mainstem bronchus. Nonventilation of this
pulmonary segment combined with a high risk of regurgita-
tion without adequate preoperative fasting and intraoperative
orogastric drainage may result in postoperative pneumonia, a
common cause of early death after surgery in sheep.36,37
Paraplegiamay develop in rabbits after infrarenal aortic clamp-
ing for placement of aortoiliac conduits,38 and anesthetic
complications may result in an operative mortality of 30%.39
Mortality rates of 10% to 30% have also been reported in dogs
and pigs.40,41 These figures should be included in published
reports to enable more accurate calculation of the number of
animals required to achieve statistical power.
COMPARISON OF SPECIES USED IN THE
ASSESSMENT OF VASCULAR CONDUITS
The ability of animals to correctly model the human
response to vascular prosthetics is determined by species
differences in factors that influence conduit performance.
For instance, comparative studies have shown that the
clotting and fibrinolytic systems of the calf and nonhuman
primates are more similar to the human than those of dogs
or pigs, and interspecies differences also exist regarding
neointimal formation.42 Knowledge of these differences
reduces the potential for bias in the interpretation of testresults and allows an assessment of the validity of the model
used.
In 1993 the Ad Hoc Committee of the Joint Councils
of the Society of Vascular Surgery and the International
Society for Cardiovascular Surgery, North American Chap-
ter, recommended that the dog be used for preclinical
testing of arterial grafts in most instances.19 This was due to
an apparent lack of significant spontaneous endothelializa-
tion of prosthetic surfaces (reflecting the situation seen in
humans) and a tendency towards hypercoagulability, mak-
ing the canine a potentially stringent challenge for conduit
assessment. As a result, canine models were frequently used
throughout the 1990s (see Table I).
With concern for animal rights increasing, the expense
and difficulty of acquiring dogs for experimental use has
also risen as the use of purpose-bred animals replaces the
relatively inexpensive mongrel so that pigs and sheep are
now comparatively cheap to purchase.23,43 Recent studies
have also questioned the appropriateness of canines for the
assessment of endothelialization and patency, as discussed
later.29,44-47 Nonhuman primates resemble human anat-
omy and physiology more closely than other species, but
their use is limited for many by ethical considerations,
prohibitive cost, and their protected status.23,42
COMPARATIVE HEMATOLOGY
The acute response of the blood to materials implanted
into the vascular circulation results from a complex inter-
play between a number of interconnected systems that
include platelets, coagulation proteins, and cellular ele-
ments such as macrophages, and has been summarized
elsewhere.48 Briefly, adsorption of plasma proteins to the
material surface is followed by platelet activation and at-
tachment resulting in shape change and release of cytoplas-
mic granule contents. Delivery of additional platelets and
proteins to the surface, influenced by the effects of blood
flow and wall shear stress, results in a luminal coating of
platelets and fibrinogen/fibrin that may lead to thrombotic
occlusion of the conduit. These thrombotic processes are
balanced by a number of regulatory mechanisms such as the
fibrinolytic system. Comparisons of the coagulation sys-
tems of species therefore examine the response of platelets
to surfaces (attachment/activation) and to agonists of the
release reaction (eg, adenosine diphosphate, collagen, epi-
nephrine, thrombin, ristocetin) as well as levels of coagula-
tion cascade proteins and times to achieve coagulation end
points, including thrombin, prothrombin, and activated
partial thromboplastin times.
An appreciation of the comparative hematology of
commonly used species is essential when determining the
validity of the in vivo thrombogenicity assessment of vas-
cular biomaterials. Relevant hemodynamic and hemato-
logic values for commonly used animals compared with
humans are given in Tables III and IV, and these animals
are discussed in detail below. Owing to variability in normal
values, depending on methodology, values for coagulation
tests are best compared with normal control animals at the
same time and in the same laboratory.49-54 For most mam-
an blo
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weight (L/kg).55
Historical studies of platelet responses to biomaterials
or other stimuli, as well as for other aspects of the hemo-
static system such as activation of the coagulation pathway,
are available for all commonly used species. Similar studies
also exist for other animals, including camelidae (camels,
llamas),56 goats,57 and guinea pigs.58 It is important to
remember that species differences are biomaterial depen-
dent, with the response of any given species significantly
affected by the material being investigated.59 Furthermore,
laboratory measures of coagulation cannot be used in iso-
lation to predict graft performance; for instance, canines
demonstrate generally superior patency for ePTFE con-
duits compared with sheep despite shorter coagulation
times in vitro.44,60
Baboon. Baboons exhibit a high degree of genetic
similarity with humans,61 so it is unsurprising that the
hemostatic system of humans is most closely approximated
by the baboon and other Old World primates.62-64 In a
comparative study, Feingold et al65 found that baboons
demonstrate a similar fibrinogen level and thrombin time
to humans, and the prothrombin time (PT) and activated
partial thromboplastin time (APTT) are only slightly in-
creased, whereas they are significantly shorter in canines.
Baboon factor VIII activity is also similar to humans, and
factor VIII antigen cross-reacts with human factor VIII
antibodies. Baboon platelets demonstrate several similari-
ties, including size distribution, number of dense bodies,
Table III. Hemodynamic valuesa for some commonly use
Species
SBP
(mm Hg)
DBP
(mm Hg)
Human43,204 126  14 79  10
Baboon55,205-208 122 77
Pig43,209 127  8 86  7
Sheep43,209,210 140 90
Dog43,209 126  23 90  20
Rabbit49,146,209,211,212 120 80
Rat49,209,211,212 127  7 85  15
CI, Cardiac index; DBP, diastolic blood pressure; HR, heart rate; MBP, me
aValues are presented as mean  standard deviation or range.
Table IV. Hematology valuesa for some commonly used
Species
RBC
(109/mL) Hct (%)
P
(1
Human43,204,211 4.8-5.4 44.5  8 265
Baboon54,61 4.5 36.2  2 370
Pig43,209,211,213 6-8 41 350
Sheep43,209,211,213 10-13 36  9 550
Dog43,209,211,213 6-8 45  10 350
Rabbit55,209 4-7.2 42.5  3 200
Rat55 7-10 46.4 500
Fib, Fibrinogen; Hct, hematocrit; Neut, neutrophils; Lymph, lymphocytes; P
aValues are given as mean  standard deviation or range.and responsiveness to collagen and ristocetin, althoughwith increased responsiveness to arachidonic acid and re-
duced responsiveness to adenosine diphosphate (ADP) and
epinephrine. The baboon is also immunologically closest to
humans.66
Sheep. Sheep have been described as possessing a co-
agulation system that is closer to the human than either
dogs or pigs,42 although a number of differences are nota-
ble in the assessment of the thrombogenicity of vascular
prostheses. Platelet number is high compared with most
species (3-8  105/mL vs 2-5  105/mL),49 and adhe-
siveness is increased. Sheep also demonstrate reduced fi-
brinolytic activity, and together, these attributes confer a
tendency toward hypercoagulability.43,67 Compared with
humans, platelet aggregation is similar with thrombin,68
ADP,69 and platelet-activating factor (PAF),70 is reduced
with collagen type I and ristocetin,69 and is nearly absent
with epinephrine.68,69
The cellular blood elements also show some differences
between sheep and humans, with erythrocyte values of
particular relevance. Ovine red blood cells are relatively
small and the sedimentation rate is slow due to the absence
of rouleau formation in ruminants.67 This should be con-
sidered when separating sheep blood by differential centrif-
ugation, for example, when isolating platelets, because
higher centrifugation speeds may be required when sheep
are used69 than those recommended for human blood.71
Sheep red cells are also more osmotically fragile than hu-
man red cells, with hemolysis beginning at 0.65% to 0.76%
cies
BP
Hg)
HR
(beats/min)
CI
(mL/min/kg)
TBV
(mL/kg)
 11 70  14 93  20 80
 16 92  13 103 60-80
 9 105  10 99  20 57
14 95  24 115  31 58
 7 98  18 88  19 93
 3 130-325 279  56 56
 8 250-450 441  142 54
od pressure; SBP, systolic blood pressure; TBV, total blood volume.
es
)
WBC
(109/L)
Neut
(%WBC)
Lymph
(%WBC)
Fib
(g/L)
5 7.4  3.4 50-70 20-40 2-4
5 7.1  2.1 44 46
0 14.8 40 50 2-4
0 8  4 30 60 2-4
0 11.5  5.5 60 25 1-4
7.5-13.5 30 55
6-17 9-34 65-85
telet count; RBC, red blood cell count; WBC, white blood cell count.d spe
M
(mm
95
107
102
1
96
98
120speci
lt
09/L
 13
 10
 15
 25
 15
-1000
-1300
lt, plasaline and complete at 0.40% to 0.45%.67,68 Leucocytes are
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form the main proportion in sheep.68
Tillman et al69 studied platelet function and coagula-
tion parameters in healthy unanesthetized sheep as well as
from sheep during vascular surgery and compared these
with human values. Results for PT, APTT, activated coag-
ulation time (ACT), platelet counts, and platelet aggrega-
tion were unaffected by anesthesia and surgery, with the
exception of prolongation of PT, APTT, and ACT by
systemic administration of heparin, which were all fully
reversed with protamine sulfate. Coagulation parameters
from healthy sheep were similar to human values, as was
platelet aggregation due to ADP. Ovine platelet counts
were slightly higher as expected.
Pig. Like sheep, pigs have also been attributed with a
coagulation system that is similar to humans,72,73 although
with a tendency towards hypercoagulability.42 Pelagalli et
al compared buffalo, horse, pig, and sheep platelets for their
ability to aggregate in response to agonists74 and to attach
to immobilized autologous fibrinogen.75 Pig platelets were
more responsive to ADP than sheep, but sheep platelets
demonstrated greater sensitivity to ristocetin, collagen type
I, and PAF. Platelet attachment to immobilized fibrinogen
both with and without activation by ADP was greatest for
humans, lowest for sheep, and in between for pigs. Sheep
platelets were unable to attach in the absence of ADP.
Platelet attachment to pyrolytic carbon mechanical
heart valve leaflets, polyethylene, silicone rubber, and
Formvar (polyvinyl formal resin) was compared between
sheep, pigs, and humans.76 Scanning electron microscopy
was used to assess attachment and spreading after exposure
to the materials under static conditions and found similar
results in pigs and humans and a comparatively reduced
platelet response in sheep. The low numbers in this study,
however, limit generalization.
Dog. Despite also being attributed with a hematologic
system similar to humans, the dog is known to be relatively
hypercoagulable43 and exhibits greater dissimilarities to
humans than do sheep or pigs. Whittle et al77 found
sensitivity of canine platelet aggregation to ADP was low
compared with humans and sheep, and inhibition of aggre-
gation by prostaglandin D2 was weak. The fibrinolytic
system is more active in the canine than in the pig.42
Canines have a significantly shorter PT, APTT, and throm-
bin time than humans and may have significantly higher
concentrations of fibrinogen.65 Factor VIII activity is
markedly higher than in humans or baboons, and canine
factor VIII antigen fails to cross-react with human factor
VIII antibodies. Platelets from dogs are slower to aggregate
in response to collagen and show less aggregation to epi-
nephrine and ADP. Sato and Harasaki60 used a clot signa-
ture analyzer to compare platelet-mediated hemostasis,
collagen-induced thrombus formation, and clotting time
between human, bovine, ovine, and canine species. All
three parameters were similar between sheep and humans,
but distinctly shorter times were found in dogs. They
concluded that, “the dog is not an ideal animal model for
the evaluation of blood-surface interactions.”Rabbit and rat. The rabbit may provide a more valid
model for thrombogenicity assessment than the rat due to
greater similarities in hemostatic mechanisms with humans.
These include a coagulation system which resembles more
closely that of the human and arteries with similar throm-
boplastic and fibrinolytic properties.78 Differences in plate-
let aggregation to agonists include relatively less sensitivity
of rabbit platelets to ADP than those of humans or rats,77
whereas rabbit platelets are more sensitive to PAF than
human platelets and show a different response and release
pattern. Platelets from rats do not aggregate or release
when exposed to PAF.70
A comparison of rat and human hematology and coag-
ulation found a number of similarities as well as differen-
ces.79 Platelet count averaged 1109  109/L for rats with
a mean diameter of 2 m, which is more numerous and
slightly smaller than human platelets. Compared with hu-
mans, platelet aggregation in rats was reduced or absent
with collagen, ristocetin, thrombin, epinephrine, and ara-
chidonic acid but similar with ADP. Levels of coagulation
factors were mostly similar; however, PT and APTT were
shorter than in humans and thrombin time was longer, with
a low-grade thrombin inhibitor detected in rat plasma.
COMPARATIVE HYDRODYNAMICS OF
COMMON IMPLANT LOCATIONS
Knowledge of relevant hydrodynamic values for com-
mon implant locations in animal models used for vascular
conduit assessment allows informed decisions to be made
about the applicability of experimental results to clinical
practice.We hope that the summary of values provided here
also facilitates the design of future animal studies by pro-
viding an indication of values that can be expected from
various implant models (Table V). For example, 5.5-mm-
diamater saphenous vein implanted as femoral artery bypass
grafts in dogs80 achieve a mean flow of 170 mL/min and a
mean shear stress of 18 dynes/cm2, similar to values for the
native canine femoral artery.28
A number of factors should be considered when inter-
preting published values for vessel diameter, blood flow,
and shear stress. Values within species will vary due to a
number of factors, notably the size of the animal given the
positive association between body weight and cardiac out-
put or blood vessel flow.81 This relationship is stronger for
the common carotid artery than for the femoral artery,81 at
least in the canine, and is not significant in small animals
such as the rat.82 The origin of the animal may also confer
an important influence: compared with mongrel dogs, rac-
ing greyhounds demonstrate a higher mean arterial pres-
sure, higher cardiac index, lower peripheral vascular resis-
tance, lower vascular impedance, and a femoral artery blood
flow of 179 mL/min compared with 80 mL/min for
mongrels.83 The timing of assessment is crucial due to the
effects of anesthesia and surgery, with increased blood flow
seen, for example, after arterial clamp removal due to
postischemic hyperemia.84 Lastly, it is important to be
precise regarding the anatomic location; for instance, the
wrap
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than in the abdomen.85
LARGE-ANIMAL MODELS FOR THE
ASSESSMENT OF NOVEL VASCULAR
CONDUITS
Large domestic animals have generally been used for
the evaluation of cardiac and vascular biomaterials because
of a closer resemblance to human anatomic and physiologic
characteristics than that obtained from models in other
mammals such as rabbits or rats.43 Commonly used species
include the baboon, sheep, pig, and dog, accommodating
conduits mostly 3 to 6 mm in diameter although up to 8
mm in the canine aorta.
Baboon (primate, nonhuman). As outlined earlier,
the baboon provides the closest approximation to humans
for the assessment of blood compatibility of vascular sur-
faces. The baboon is also frequently used in the assessment
of endothelialization of prosthetic conduits, usually in the
iliac position. Despite a higher purchase cost, the overall
expense may be balanced in some countries bymaintenance
costs below that for more difficult species such as pigs.23,49
The effect of modifying the luminal surface of vascular
prosthetics on acute thrombogenicity is conveniently stud-
Table V. Valuesa of relevant hydrodynamic variables for c
Species, location Diameter (mm)
M
(m
Human
CCA214-216 6.5, 7.0 45
CFA217,218 8.0, 10.2 28
SFA217,218 6.2, 8.3 15
Baboon
CCA98,206 3.2c
IA219,220 2.5d,e 1
Sheep
CCA111,221,222 5.6, 7.2
IA223 5.9
CFA111,122,221 4.2, 5.0
Dog
CCA28,81,82 3.0-4.0
Abdo.Ao85,224 6.0-7.0, 8.0 4
IA225-228 3.2, 4.9, 7.4 84, 97
FA28,81-83 4.4, 4.0-5.0 80,
Rabbit
CCA82,229,230 1.9-2.1, 2.0
Abdo.Ao39,137,139 2.5-3.0, 3.0 3
FA82,143 1.0-1.2
Rat
Abdo.Ao154,162,163 1.0, 2.0
Mouse
Abdo.Ao165 1.0
Abdo.Ao, Abdominal aorta; CCA, common carotid artery; CFA, common f
WSS, wall shear stress.
aValues are presented as mean or range.
bCalculated from average values for diameter and flow. Viscosity of blood 
cAt 30 days after implantation of heparin-coated stent, calculated from lum
dAfter bilateral placement of aortoiliac prosthetic grafts.
eAt 4 days after placement of an external expanded polytetrafluoroethylene
fAt implantation of 3.6/4.0-mm diameter interposition graft.ied by imaging implanted conduits for the attachment ofradiolabeled compounds. This method has been shown to
be suitable across all commonly used animal models.86,87
Jordan et al62 recently assessed the acute thrombogenicity
of a novel “elastin-mimetic” coated ePTFE conduit in-
serted in a baboon arteriovenous shunt. Using autologous
111Indium-labelled platelets and 125Iodine-labelled fibrin,
evidence for the use of recombinant elastin polymers as
nonthrombogenic coatings was greatly strengthened by the
demonstration of minimal attachment to the treated sur-
face over 60 minutes at 100 mL/min blood flow.
As with thrombogenicity, the use of animals for the
assessment of endothelialization is complicated by species
differences. The incomplete endothelialization of ePTFE
that characterizes human implants has also been attributed
to baboons;63 however, others have found comparatively
rapid healing of arterial synthetics placed in baboons as well
as pigs and dogs.88 Clowes et al89,90 implanted ePTFE
conduits in baboon carotid and iliac arteries and showed
60% of conduits 7 to 9 cm in length fully endothelialized
after 12 months, with endothelialization occurring at 0.2
mm/d. These researchers demonstrated in a further inves-
tigation the importance of ePTFE porosity on facilitating
endothelialization through transmural ingrowth: a 60-m
internodal distance resulted in complete endothelial cover-
on implant locations
ow
n)
Mean velocity
(cm/s)
Mean WSS
(dynes/cm2)
3 22.3, 24.4, 21.8b 7.8, 10.4b
9 8.6, 10.2, 8.2b 2.9b
6 7.5, 8.8, 7.0b 3.1b
12.6b 12.6b
55.0d, 74.2e, 57.7b 37.5e, 73.9b
16.8b 8.4b
16.0b 11.2b
26.5b 27.0, 24.2b
0 21.9b 10.0b
, 137 13.9, 8.4b 11.0, 17.8, 5.2b
02 13.5b 14.0, 9.7b
26.4b 9.1-10.3, 42.3b
f 10.7b 11.9b
l artery; FA, femoral artery; IA, iliac artery; SFA, superficial femoral artery;
Poise.
neointimal area.
around the iliac artery.omm
ean fl
L/mi
5, 48
4, 35
2, 19
61
70d
325
160
153
30-58
, 105
97, 2
49.8
2-51
emora
0.04
inal age in baboons, whereas a 30-mdistance limited coverage
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ilarity between baboons and humans, these results failed to
translate successfully in human clinical trials using 60-m
ePTFE reinforced with an outer wrap.92
Nevertheless, the use of baboons has contributed sig-
nificantly to the development of endothelial cell (EC) seed-
ing to improve the long-term patency of synthetic conduits.
Zilla et al93 implanted ePTFE conduits coated in vitro with
autologous ECs into baboon femoral arteries and demon-
strated retention of a nonthrombogenic endothelial surface
after 4 weeks. They went on to develop and clinically apply
in vitro endothelialized ePTFE conduits in 130 patients,
achieving a 7-year primary patency rate for infrainguinal
grafts of 63%.94
The use of baboons has also advanced our understand-
ing of anastomotic IH through studying the healing re-
sponse to implanted vascular conduits as well as other forms
of vascular injury. Late failure of vascular conduits occurs as
a result of stenosis and occlusion from IH, which occurs
most commonly around the distal anastomosis. Contribut-
ing events include compliance mismatch, turbulent flow,
and altered wall shear stress leading to endothelial injury,
platelet activation, cellular proliferation, and the deposition
of extracellular matrix.14,95-97
A number of models are available for the study of IH
and restenosis after arterial insult, although these often use
nonsurgical methods to generate localized endothelial and
mural injury, most commonly by inflating and withdrawing
a Fogarty balloon catheter. These methods have been used
to experimentally produce complex lesions, similar to those
seen in humans, in nonhuman primates and pigs. Sheep,
dogs, rabbits, and rats have also been used to study IH and
restenosis after stent placement. Like the response to vas-
cular grafting, stenosis after stent implantation occurs due
to IH, whereas constrictive remodeling (loss of area within
the external elastic lamina) predominates after balloon an-
gioplasty.42 Not surprisingly, the same species have also
been used to assess IH after implantation of vascular con-
duits, including baboons, rhesus monkeys, pigs, sheep,
dogs, rabbits, and rats.36 Lin et al98 demonstrated in ba-
boons that carotid stenting using a heparin-coated balloon-
expandable stent reduced IH compared with uncoated
stents. Chen et al61 demonstrated reduced IH at the distal
anastomosis of ePTFE aortoiliac bypass grafts in baboons
after 4 weeks of exposure to a perianastomotic heparin
infusion. More recently, Zilla et al99 assessed midgraft-IH
in vein grafts to the baboon femoral artery and showed
reduced IH in the presence of a constrictive external nitinol
mesh. These authors have also compared the response of
baboon and sheep models to xenogenic tissue using por-
cine stentless bioprosthetic heart valves and found a stron-
ger acute xenograft response in the primate compared with
more calcification and foreign body-type reaction in the
sheep.66
Sheep (ovine). The sheep is one of the most widely
used animal models for the evaluation of implanted cardio-
vascular devices and has served as the gold standard for
models of bioprosthetic heart valve research for de-cades.66,76 Numerous advantages include being relatively
low cost and an easy animal to manage in the laboratory as
well as presenting a stable size and suitable anatomy for the
implantation and monitoring of conduits 4 to 6 mm in
diameter as carotid or femoral artery implants.23,42 Mea-
sures of blood coagulation in sheep undergoing vascular
surgery are similar to those found in humans, but these
animals do exhibit a number of hematologic differences
along with a tendency to hypercoagulability, as outlined
earlier. Sheep can be anticoagulated with heparin and war-
farin, although at generally higher doses than those used for
humans; however, the response to clopidogrel is modest,
and aspirin fails to inhibit platelet aggregation.100-102
Carotid artery interposition. The ovine carotid ar-
tery is readily accessible and similar in diameter to human
peripheral arteries. In addition, implantation of conduits in
the neck is well tolerated, with minimal postoperative mor-
bidity.23,36,103 Neurologic complications as a result of graft
implantation or subsequent occlusion seem rare despite
temporary bilateral common carotid artery (CCA) occlu-
sion during insertion or permanent loss of patency postop-
eratively, in keeping with the known anatomy and physiol-
ogy of ovine cerebral blood flow.
Unlike most other species, the basilar artery in the
sheep has only tenuous connections with the vertebrals,
which instead communicate with the distal CCAs by a
well-developed occipitovertebral anastomosis. From here,
blood flows cranially through the external carotid artery on
each side to eventually reach the circle of Willis.104 Blood
from each CCA is unilaterally distributed to the cephalic
area, but occlusion of one side results in bilateral distribu-
tion due to flow through the available anastomoses.105
Occlusion of one or both CCAs causes increases in blood
flow and pressure in the remaining CCA or vertebral arter-
ies, or both.106,107 Unilateral CCA occlusion is well toler-
ated, but temporary bilateral occlusion results in changes in
the amplitude and frequency in the electroencephalogram
of anesthetized sheep, or swaying and ataxia without loss of
consciousness in awake sheep. Clamping both CCAs after
previous ligation of both occipitovertebral anastomoses
invariably results in abolition of the electroencephalogram,
as does clamping of both external carotid arteries.108 Sur-
prisingly, sheep generally recover24 hours from even this
complete ischemia so long as it lasts no longer than 12
minutes, beyond which they exhibit blindness, ataxia, and
death.109 Sequential occlusion due to stepped loss of pa-
tency postoperatively may be better tolerated due to en-
largement of the remaining vessels and development of
collaterals.110
Dunn et al111 found preimplantation flows in the ca-
rotid to be twice that seen in the femoral artery despite the
similarity in size (325  108 vs 160  70 mL/min).
Despite use of lignocaine to reduce arterial spasm, postim-
plantation flows were also more profoundly reduced in the
carotid (236  47 mL/min) than the femoral (153  60
mL/min) after insertion of 4-mm diameter conduits. This
may be attributed to a slightly greater size mismatch in the
carotid position or to greater spasm in the more muscular
JOURNAL OF VASCULAR SURGERY
July 2010184 Byrom et alcarotid artery. Lundell et al87,112,113 investigated the effect
of blood flow by implanting bilateral carotid conduits and
reducing flow to 25 mL/min on one side, demonstrating
greater platelet and fibrinogen uptake and reduced patency
for conduits exposed to reduced flow.
To provide a useful model for the assessment of pa-
tency, control conduits need to exhibit an occlusion rate
sufficient to allow a significant patency difference to be
demonstrated within a practical timeframe. Unmodified
ePTFE conduits have shown 50% patency at 1 month for
5-mm-diameter carotid implants,36 dropping to 33% (5
mm)36 or 0% (4 mm)114 after 3 months.
In addition to the assessment of conduit thromboge-
nicity and patency, sheep have frequently been used as a
model for anastomotic IH. Taylor et al115 and Simoni et
al37 implanted ePTFE conduits as carotid artery grafts in
sheep and showed a reduction of IH with systemic heparin
administration postoperatively. Ao et al116 and Hawthorne
et al117 used patches of synthetic graft materials placed in
the carotid artery to compare the hyperplastic response to
the various polymers and develop a new methodology for
IH assessment. Ueberrueck et al72 implanted polyester
conduits as sheep carotid bypass or pig aortic interposition
grafts and assessed IH at 3 months. They found no differ-
ence between species, although the differences in anasto-
motic geometry, animal maturity, and possible size mis-
match for these 8-mm-diameter conduits are important
uncontrolled confounding factors. In addition to patches
and arterial grafts, arteriovenous grafts between the carotid
artery and jugular vein have been used in sheep to model
the IH seen at the venous anastomosis of hemodialysis
access grafts, with a thick neointima developing within 4
weeks.118
Femoral artery. Despite a slightly smaller size and a
lower blood flow, ePTFE conduits implanted in the femo-
ral position have shown similar patency rates to the carotid.
Christenson et al119 inserted 4-mm ePTFE conduits in the
femoral artery and showed 50% patency at 1 month and
33% at 3 months. Like the carotid, the femoral position is
suitable for the assessment of acute thrombogenicity by the
measurement of conduit radioactivity in response to uptake
of 111Indium-labelled autologous platelets. Peak attach-
ment occurs about 60 to 90 minutes after restoration of
blood flow, with little activity seen at 3 or 4 days after
implantation, despite adjustment for decay.119,120 Re-
searchers have also found this location convenient to assess
anastomotic IH in response to femoral artery bypass grafts
and the effect of using vein cuffs, demonstrating reduced
IH at the vein-artery anastomosis.121,122
Pig (porcine). Human cardiovascular anatomy and
physiology is closely represented in the pig, with their
nearly identical coronary vasculature making pigs ideal for
the study of ischemia-reperfusion and coronary stent tech-
nology.43 The arterial morphology of the pig is also similar,
but their arteries are smaller and show greater fragility.42,43
Other advantages include ready availability and low pur-
chase cost. In some respects, the pig offers a similar model
to the sheep for the assessment of vascular conduits, withsimilarities in platelet function and coagulation to humans
and a propensity for calcification of biomaterial implants.68
In contrast to sheep and dogs, however, swine are
infrequently used for testing of vascular conduits. Disad-
vantages include greater difficulties in handling, less toler-
ance of anesthesia, and maintenance costs may be higher.42
A recent comparison study72 found that operative time was
similar for sheep carotid and pig aortic implants and costs
were comparable; however, sheep afforded easy assess for
ultrasound imaging at follow-up, which was not possible in
pigs. In addition, complete endothelialization was found in
all polyester conduits after 3 months in pigs but only
perianastomotic endothelialization was seen in sheep,
which represents more closely the situation seen in humans.
The main disadvantage, however, is the rapid growth
inherent in commonly available strains of swine, with a
typical 25-kg pig weighing about 100 kg 8 weeks later.23
Using this growth to their advantage, Robotin-Johnson et
al40 implanted grafts of small intestine submucosa with a
mean diameter 11.7 mm and length 9.9 mm into the
thoracic superior vena cava of piglets to assess the ability of
the grafts to grow with the animal over 3 months. During
this time, the piglets’ weight increased 575%, from a mean
10.3 to 59.2 kg, and the grafts increased to a mean diam-
eter of 19.5 mm and length of 15.8 mm (unresected
superior vena cava controls: 19.5-mm diameter, 23.8-mm
length), demonstrating the potential of this material as a
cardiovascular substitute in growing children. Niklason et
al123 used Yucatan minipigs, which like sheep show little
adult growth.23,124 The minipigs received autologous tis-
sue conduits grown in vitro then implanted as interposition
conduits into the saphenous artery, a branch of the femoral
artery supplying the distal hind limb, and demonstrated
their utility during a 4-week period.
The pig is currently the species of choice for the in vivo
evaluation of vascular balloon injury, stenting, and resteno-
sis, particularly for coronary studies but also for more
peripheral vessels.43 As in humans, there is a proportional
relationship between vascular injury and neointimal re-
sponse that is most marked in swine, intermediate in ba-
boons and rabbits, and almost flat in dogs.42 The pig
femoral artery has been used to study IH after balloon
angioplasty125 as well as the use of vein interposition cuffs
to reduce the intimal hyperplastic response to ePTFE by-
pass grafts.126
Recently, this animal has been used to investigate the
particular problem of IH at the venous anastomosis of
arteriovenous grafts used for hemodialysis access, with po-
tential applicability to prosthetic conduit-induced IH in
general. This problem has long been recognized clinically
in humans where the known stimuli at the distal anastomo-
sis of compliance mismatch, turbulent flow, and altered
wall shear stress are exaggerated by the presence of high
flow through the conduit (typically 1.0-1.5 L/min) as well
as repetitive puncture resulting in ongoing endothelial
injury, platelet activation, and myointimal proliferation.127
Therapeutic strategies attempting to reduce IH affect-
ing carotid artery-jugular vein ePTFE grafts in swine in-
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muscle cell (SMC) proliferation128 and coating ePTFE
grafts with anti-CD34 antibodies intended to capture cir-
culating endothelial progenitor cells.129 Roy-Chaudhury et
al130 placed ePTFE conduits as femoral arteriovenous
grafts in pigs, showing almost complete abolition of lumi-
nal stenosis by wrapping the graft-vein anastomosis with a
paclitaxel-loaded wrap.130
Dog (canine). Experimental surgery using canines has
an extensive history, and as animal models they possess a
number of advantages. Dogs are usually familiar with hu-
mans, making them easy to handle, and mongrel dogs are
readily available and inexpensive. Canine cardiovascular
physiology is similar to that of humans, dogs possess low
body fat, and vascular access is relatively straightforward.43
Peripheral arteries are available in diameters from 3 to 5
mm, and the aorta can accommodate interposition grafts
up to 8 mm diameter. Dogs are also tolerant of prolonged
anesthesia.42
Increasingly, however, disadvantages are reducing the
favored status of dogs for the in vivo assessment of novel
vascular conduits. It has long been known that platelet
reactivity in the dog is variable and not reliably measured in
vitro, and the screening and classification of subjects by
platelet aggregometry is imperfect. The use of bilateral
implants with a test and control conduit in each animal is
therefore highly recommended to reduce the effects of
inter-individual variations in thrombogenicity in all animal
models but especially in canines.30 Also apparent is the
changing mood of society towards the use of canines for
research, and the cost of using dogs is rising sharply as a
consequence.42,43 The viscoelastic properties of canine ar-
teries are different from those in humans, being more
elastic overall and showing less increase in wall stiffness in
the more peripherally situated arteries. The carotid artery in
the dog demonstrates a particular dissimilarity, being mus-
cular like the femoral artery of the dog and human rather
than elastic like the human carotid.32 The tendency toward
hypercoagulability has been highlighted, but further scru-
tiny of comparative studies draws attention to the dissimi-
larities between human and canine hemostatic systems and
emphasizes the greater similarity shown by sheep or pigs
and especially nonhuman primates such as baboons.
Early studies in dogs used large vessels such as the
thoracic or abdominal aorta, which can accommodate con-
duits 6 to 8 mm in diameter. Expansion into other territo-
ries began in the late 1960s,43 leading to implantation of
smaller conduits as CCA interposition (3- to 5-mm) or
aortoiliac bypass (4- to 5-mm) grafts generally 4 to 6 cm in
length. To perform a more demanding assessment of a
length more closely resembling clinical use, Marois et al131
inserted 30-cm-long conduits as thoracoabdominal aortic
bypass grafts in adult mongrel dogs for up to 6months. The
flow rate is high in this position, and the authors recom-
mend that the model be used primarily for the evaluation of
surface thrombogenicity and healing rather than as a pa-
tency challenge, with all test conduits remaining patent in
this study. Randall et al132 were able to assess conduits 45cm in length by dividing and anastomosing the distal
CCAs, then implanting a 6-mm-diameter conduit from this
common lumen to the distal aorta, with patency again
remaining high out to 12 months. Conduits 60 to 70 cm in
length have also been implanted subcutaneously in dogs.41
Compared with sheep, control conduits such as ePTFE
and Dacron implanted in canines have shown relatively
high patency rates, questioning the belief that dogs provide
a stringent assessment of conduit patency. At 4 months,
86% of 4-mm-diameter ePTFE andDacron conduits placed
as aortoiliac bypass grafts in dogs remained patent,84 while
75% of 5-mm ePTFE grafts remained patent after 6 months
in the same location.133 Wilson et al31 found an overall
3-month patency of 77% across forty-eight 4-mm ePTFE
conduits inserted as carotid or femoral interposition grafts,
and noted that in their previous canine studies, few throm-
botic occlusions occurred 3 months after implantation
and almost none thereafter. In a direct comparison, Orten-
wall et al44 placed 4-mm ePTFE conduits as CCA interpo-
sition grafts in both sheep and dogs and assessed their
patency at 2 and 5weeks. For grafts seeded with autologous
ECs, patency was 75% and 83% in dogs at 2 and 5 weeks
respectively, but 0% and 11% for sheep. More importantly
for unseeded control grafts, patency was also 75% and 83%
for dogs but only 40% and 0% for sheep.
Possible explanations for these species differences in
patency include differences in flow, coagulation, and/or
conduit healing. Despite generally being somewhat larger,
sheep have demonstrated similar values to their canine
counterparts for carotid and femoral blood flow (Table V).
Both species have been described as being relatively hyper-
coagulable, but shorter coagulation times have been seen in
dogs compared with sheep or humans,60 which would be
expected to lead to reduced patency in dogs. On the other
hand, canine models generally use aspirin to reduce the
known problem of platelet aggregation31,44 and this may
contribute to increased patency.
A major contributing factor, however, is the rapid
“spontaneous” endothelialization of vascular prosthetics
that has been demonstrated to occur in dogs.29,45-47
ePTFE and Dacron conduits explanted from humans show
ECs over the perianastomotic regions but these never ex-
tend more than a short distance over the luminal surface of
the prostheses, which instead is covered with fibrin or
collagen (mostly type III), or both.134 As a result, endo-
thelialization in humans must rely on transmural tissue
ingrowth or blood-borne sources due to the conduit
lengths implanted in typical bypass grafts.29 Dogs, mean-
while, can quickly endothelialize synthetic conduits by all
three mechanisms.29,88,135 Zilla et al29 emphasized the
importance of selecting the appropriate model for the
assessment of prosthetic vascular grafts, particularly in re-
gard to the assessment of endothelialization. Species is the
major factor determining the rate of transanastomotic en-
dothelialization (along with graft surface and dimensions
and also animal senescence), with dogs able to cover in 3.5
weeks the ingrowth distance that humans would take more
than a year to accomplish.29 The baboon, dog, pig, and calf
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aspect of arterial prostheses, in marked contrast to hu-
mans.47,90
In summary, the preferential use of dogs in the preclin-
ical assessment of arterial grafts can no longer be supported
in light of studies challenging the assumptions of low
patency and lack of spontaneous endothelialization attrib-
uted to prosthetic vascular conduits implanted in the ca-
nine. The increasing reluctance of society to the use of dogs
for animal experimentation is also a contributing factor.
Sheep, meanwhile, demonstrate the same qualities that led
to the original recommendation to use dogs for vascular
conduit assessment: a relatively high occlusion rate and
restriction of endothelialization to the perianastomotic re-
gions. This greater ability to correctly model the human
response to vascular conduits, combined with the other
advantages previously stated, means that sheep are the large
animal of choice for the assessment of novel vascular con-
duits. Nonhuman primates such as the baboon offer greater
similarity for thrombogenicity assessment but the restric-
tions surrounding their use limit their availability.
SMALL-ANIMAL MODELS FOR THE
ASSESSMENT OF NOVEL VASCULAR
CONDUITS
Small animals are cheaper to purchase and maintain
than larger alternatives and they are easier to handle. Their
size, however, presents a technical challenge for the surgical
implantation of vascular conduits.23 Rabbits and rats are
the predominant small animals used, generally accommo-
dating small diameter (2- to 5-mm) conduits in rabbits and
very small (2-mm) diameter conduits in rats.
Rabbit (leporine). Rabbits provide a useful model for
the assessment of small-diameter conduits, being able to
accommodate a range of conduit sizes across different
locations: aortoiliac bypass (up to 5-mmdiameter),38 aortic
interposition (3-4 mm),39,136-139 carotid interposition
(generally 2 mm)78,140-142 and femoral interposition (1-
1.5 mm),143-145 with lengths up to 4 or 5 cm in most
locations. For carotid and femoral procedures, other advan-
tages include simple anesthesia and the availability of bilat-
eral implantation.140
Carotid artery interposition. Carotid artery grafting
is convenient in the rabbit. Up to 5 cm of carotid artery can
be exposed bilaterally through a midline incision accom-
modating either straight grafts up to 3 cm or loop grafts up
to 10 cm in length. Bilateral conduits can be placed, and
patency is easily assessed by palpating the ipsilateral central
ear artery or by Doppler ultrasound assessment.140,142
Longitudinal tension is similar to humans, with CCAs
removed from rabbits retracting 38%.35 Like sheep, rabbits
tolerate CCA occlusion due to graft insertion or postoper-
ative loss of patency without signs of neurologic injury,
even after bilateral occlusion for 30 minutes.78,140 The
rabbit brain receives blood flow from the common carotid
and vertebral arteries by the circle of Willis, allowing supply
through anastomotic connections to continue despite iso-
lated occlusion of arterial inflow. Ligation of the internalcarotid artery, for example, results in doubling of contralat-
eral internal carotid artery flow to maintain total cerebral
blood flow.146,147 With experience, CCA grafting in the
rabbit results in a postoperative survival of 90%, with
mortality generally due to anesthetic complications.140
Cassel et al140 inserted 2-mm ePTFE grafts (n  158)
in the carotid position and found two distinct patterns of
occlusion: a failure rate of 11.2% in the first 2 weeks due to
thrombotic occlusion, then patency remained stable out to
16 weeks, beyond which progressive patency loss was seen
due to development of IH most marked at the distal
anastomosis. Autologous carotid artery grafts meanwhile
maintained 100% patency out to 32 weeks. These results
closely simulate the clinical response to chronic ePTFE
grafts seen in humans.140
The rabbit carotid model has also been shown to ap-
proximate the endothelial response to prosthetic conduits
seen in humans. Endothelialization has been found limited
to the perianastomotic regions of 2-mm ePTFE grafts in
the rabbit CCA after study at 3 weeks142 and at 8 weeks.141
The wide variation in patency of these studies, however,
serves to highlight the difficulties in finding consensus
among examples of animal models: 20% at 3 weeks and
100% at 8 weeks, respectively.
Other positions. Insertion of grafts 3 to 5 mm in
diameter in the rabbit generally requires placement in the
aortic39,136-139 or aortoiliac38 position, although size-
mismatched conduits up to 5 mm diameter have been
placed in the CCA.148,149 The disadvantage of aortic inter-
position grafting is the lack of an intra-animal control.
Nordestgaard et al136 reported 3-month patencies for
ePTFE in this position of 82% for 3-mm conduits and only
24% for 2-mm conduits, possibly due to under-sizing re-
sulting in restricted blood flow. Acute thrombogenicity can
be assessed using 111Indium-labelled autologous plate-
lets39 and patency assessed by hind limb paralysis with a
sensitivity of 94% and specificity of 89% for aortic graft
thrombosis.136 Aortoiliac grafts are amenable to follow-up
with Doppler or duplex ultrasound or even contrast-enhanced
computed tomography.38 Like the carotid, ePTFE grafts in
the aortic position show only rare endothelialization, even
after 6 months.139
The femoral artery in the rabbit can only accommodate
conduits 1 to 1.5 mm in diameter, the same as the rat aorta,
but with the potential for bilateral graft placement. Re-
ported 1-month patency for ePTFE in this position in-
cludes 92% (1.5-mm diameter)143 and 25% (1.0-mm diam-
eter).144
Rat/mouse (murine). The small size of these rodents
generally limits their use for the assessment of novel con-
duits beyond the assessment of very small grafts in the aortic
(1- to 2-mm diameter)150-155 or femoral (1-mm diame-
ter)156,157 positions, although size-mismatched grafts up
to 4 mm in diameter have been used.158 As well as being
restricted in caliber, their length also rarely exceeds 1 to 2
cm, which is problematic because re-endothelialization
from the anastomoses occurs easily in 1-cm-long grafts and
a length of at least 2 cm is required to provide a sufficient
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implanted ePTFE conduits 1 mm in diameter and 6 cm in
length as femoral artery crossover grafts in rats, achieving
80% patency at 4 weeks and demonstrating only perianas-
tomotic endothelialization. Rats have also been used to
evaluate the compatibility of vascular conduit biomaterials
outside of the circulation, with conduit segments used as
both subcutaneous159 and intraperitoneal131 implants to
assess the healing response of the host animal.
The main concern when using rats to model human
responses to very small conduits is the generally high pa-
tency rates seen for ePTFE grafts in contrast to clinical
results,78,136 and the call to move away from rats for the
patency assessment of short graft segments was made 30
years ago.160 Reports of patency are best provided in com-
parison with an acceptable control such as ePTFE, with
Pektok et al154 recently reiterating 100% patency at 6
months for 2-mm ePTFE in the rat aortic position. If no
control conduit is evaluated, the expected high patency in
this model should be stated, with examples of studies using
ePTFE available in Table II. The model has continued to
find use in the evaluation of vascular conduits when high
patency is desired, such as the assessment of intimal prolif-
eration and other aspects of graft healing. Aspects of in-
quiry have included SMC seeding of biodegradable poly-
urethanes,161 EC seeding of ePTFE,158 use of mechanical
anastomotic devices,162,163 and systemic immunosuppres-
sion to reduce intimal proliferation.164 Like many species,
however, pharmacologic strategies that look promising in
rat models of IH often fail to achieve clinical success in
human trials.42
Despite the significant technical challenge, mice have
also been used for the assessment of vascular conduits.
Lopez-Soler et al165 successfully implanted four types of
conduit in the abdominal aorta of severe combined im-
munodeficiency mice to determine their utility as tissue-
engineering scaffolds for xenogenic cells such as human
ECs. Conduits 0.7 to 1.3 mm in diameter were found to be
matched in caliber to the native aorta, and the model
allowed follow-up of patency with duplex ultrasound im-
aging or microcomputed tomography, with 1 month pa-
tency of 100% for all conduit types.
DIRECT COMPARISON OF CONDUIT
PERFORMANCE BETWEEN SMALL-ANIMAL
MODELS
Lidman et al82 implanted ePTFE conduits in the ca-
rotid and femoral arteries of dogs and rabbits, and in the
femoral arteries of rats, to determine their patency after 2
weeks compared with autogenous vein grafts. Citing the
large variability in patency both within and between species
found in previous studies, they investigated whether con-
sistent results could be obtained. Only rabbit carotid artery
grafts (1.8-mm diameter graft to 2.0-mm artery) demon-
strated an acceptable patency rate of 83%. Dog carotid
(2.0-mm graft to 3- to 4-mm artery; patency, 0%) and
femoral (3.0-mm graft to 4- to 5-mm artery; patency, 6%)
implants failed compared with vein graft controls (100%patency both locations), although with an appreciable size
discrepancy, as did rabbit femoral grafts (1.0-mm graft to
1.0- to 1.2-mm artery; patency, 8%; vein graft control, 89%
patency). ePTFE in the rat femoral artery also performed
poorly (1.0-mm graft, 20% patency), although somewhat
better than the other species and with no autogenous
control. Attributing the good results of the rabbit carotid
implant to the higher flow rate in that location, the authors
recommended this model be used for future assessment of
very small vascular conduits.
Concerned with the excessively high rates of patency
for ePTFE prostheses implanted in rats, van der Lei et al78
implanted ePTFE and polyurethane conduits (1.5 mm 1
cm) into rabbit carotid arteries and assessed their patency
for up to 6 weeks compared with arterial autografts. Earlier
studies by the same group had found almost 100% patency
for both prostheses when implanted in the rat aorta. In the
rabbit, both prosthetics quickly lost patency, with 0% open
to flow beyond 1 week, whereas autografts remained 100%
patent during 2 weeks of follow-up. Rabbits were again
recommended as a more suitable model than rats, being
able to demonstrate the thrombogenicity of microarterial
prostheses closer to the clinical situation.
Campbell et al149 developed a novel autologous vascu-
lar graft by implanting a silicone elastomer rod in the
peritoneal cavities of rats and rabbits for 2 weeks, then
removing and inverting the tissue tube to create a “neoves-
sel” that was implanted into the rabbit CCA (5-mm diam-
eter  2-cm length) or rat aorta (5 mm  1 cm) for up to
4 months. Both animals demonstrated development of a
tube resembling the architecture of a blood vessel, with
4-month patency of about 70% in both models.
The selection of a small animal model can generally be
summarized as a choice between rabbits and rats. Greater
limitations in the diameter and length of conduit able to be
accommodated in rats, combined with a lack of bilateral
graft placement and a high overall patency rate for ePTFE,
make the rabbit more favored for the assessment of very
small vascular conduits.
NEW CHALLENGES IN THE ASSESSMENT OF
TISSUE-ENGINEERED VASCULAR CONDUITS
The field of vascular conduit design is increasingly
moving from the development or modification of poly-
meric biomaterials into the incorporation of tissue elements
to create tissue-engineered vascular grafts. The first gener-
ation of these grafts were ePTFE conduits endothelialized
in vitro and resulted in patencies matching vein grafts in
human trials.94 Current techniques include directed tissue
ingrowth into scaffolds that aim to mimic the extracellular
environment to achieve an off-the-shelf conduit capable of
rapid endothelialization in vivo166 and the use of wholly
autologous living tissue-engineered grafts.167 These ap-
proaches to the bioengineering of vascular conduits create a
number of new challenges in their assessment, including
novel outcome measures, a greater impact of host factors
regarding tissue ingrowth and healing, and the likely sus-
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through atherosclerotic disease.
Novel end points for outcome assessment. The
study of tissue-engineered vessels introduces a number of
novel end points for assessment in addition to previous
outcome measures that focus on graft patency. These in-
clude the retention of cells seeded in vitro when implanted
into animals, assessment of graft mechanical properties and
the effect of remodeling, and characterization of tissue
elements incorporated over time.
ECs seeded onto the conduit lumen in vitro may not
withstand arterial shear stress in vivo, necessitating assess-
ment of EC retention. Such studies have been used to
demonstrate the superiority of prolonged EC culture under
simulated flow conditions compared to static culture over-
night before animal implantation.111,168 However, the
availability of cellular markers across species is a significant
limiting factor in the use of immunochemistry to identify
cell types.169 EC identification through immunolabeling of
von Willebrand factor, for example, is available for ba-
boons, pigs, dogs, rabbits, rats, and mice, but assessment
of EC retention in sheep requires alternative meth-
ods.125,168,170-174
Cell culture techniques have extended beyond EC
seeding to develop vascular grafts that are predominantly or
wholly tissue-engineered, requiring demonstration of sat-
isfactory mechanical properties in vitro and assessments of
remodeling and long-term performance in vivo. Early at-
tempts using molds of SMCs and type I collagen to create
tubes subsequently coated with ECs before use required
external Dacron mesh support to allow even venous im-
plantation, with remodeling gradually progressing during a
6-month period.175 Niklason et al,123 in contrast, cultured
bovine or porcine SMCs seeded onto a biodegradable
polyglycolic acid scaffold in a pulsatile bioreactor system for
8 weeks and demonstrated burst strengths superior to
native vein, although implantation in minipigs did not
extend beyond 4 weeks.
L’Heureux et al176 recently reported their results using
“sheet-based tissue engineering” to develop completely
autologous living tissue-engineered blood vessels derived
from human fibroblasts and ECs without use of a polymeric
support. Initial implants as xenografts in immunosup-
pressed dogs showed a massive immune response at 14
days, leading to further testing in nude mice and highlight-
ing the difficulty faced when assessing living tissue in animal
models.176 Nevertheless these conduits attained mechani-
cal properties matching native human conduits and when
implanted as arteriovenous shunts for hemodialysis access
in humans demonstrated increased compliance during a
6-month period to approach that of the internal mammary
artery, without evidence of dilatation or aneurysm forma-
tion.167
Assessment of the structural durability of tissue-
engineered vessels is complicated by fibroblast migration
and collagen deposition at the external surface of the vessel,
potentially masking graft wall remodeling and weakening
that would otherwise lead to aneurysm or rupture. Thisencapsulation is a feature of ruminants and is also seen in
swine, but is more uncommon in primate models.3,123
Implantation of acellular conduit scaffolds for subse-
quent population through invasion of host tissues repre-
sents a promising approach for the development of an
off-the-shelf commercial product able to achieve the ideal
tissue-engineered autologous arterial graft.177 Consisting
of either decellularized connective tissue or porous polymer
tubes, these grafts must also demonstrate retention of
satisfactory mechanical properties once implanted. In addi-
tion, they require the identification and quantification of
cellular elements arriving through migration and prolifera-
tion as well as extracellular elements such as collagen and
elastic fibers deposited or remodeled by the developing
tissues.148,178 Grafts thought to closely resemble arterial
vessels on initial inspection can later be found to be less
suitable after more detailed characterization of their con-
stituent tissues.149,179
Beyond the effect of species—influence of other
host factors. The increasing use of tissue engineering in
the development of novel conduits brings greater emphasis
to the influence of host factors other than species, including
those of senescence and implant location. These effects are
well described for EC growth but are also seen in other
aspects of graft healing. Before discussion of the effects of
senescence and location, it is important to briefly outline
some of the challenges faced in the use of animal models to
simulate endothelialization of vascular conduits, as recently
reviewed by Zilla et al.29
Endothelialization can occur through luminal in-
growth from the anastomoses, transmural ingrowth of cap-
illaries from perigraft tissues, or through hematogenous
seeding of ECs or their precursors. Given the lengths of
conduit required for peripheral vascular surgery (generally
40-60 cm) the relevance of transanastomotic endotheliali-
zation is limited, although shorter lengths (10-20 cm) are
used for coronary artery grafting. The use of animal models
to study conduits mostly 4 to 7 cm in length (Table I) may
therefore lead to premature midgraft healing beyond short
periods of implantation, preventing a true representation of
the clinical situation.
To separate these mechanisms of endothelialization,
multicomponent grafts have been implanted in canines
consisting of a central test segment anastomosed between
two isolation segments to prevent transanastomotic endo-
thelialization. The central segment can also be made imper-
vious to tissue ingrowth to separate the effects of transmu-
ral and hematogenous endothelialization of the test
prosthesis.135,180 Other approaches include assessment af-
ter short implantation periods of up to 2 weeks.181
Recognition of these separate mechanisms to achieve
endothelial graft coverage has led to targeted approaches,
including coating ePTFE with antibodies designed to cap-
ture circulating endothelial progenitor cells129 or implan-
tation of ePTFE with increased porosity to allow transmu-
ral ingrowth.141 However, therapeutic modulation of
conduit pore size is additionally complicated by a number
of factors. The relationship between porosity and graft
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istics such as the actual dimensions available for ingrowth
and cellular orientation, such that 30-m ePTFE is unable
to support transmural endothelialization.29 Second, even
thosematerials with sufficient interstitial space for ingrowth
may show inhibition by another biologic mechanism most
likely arising from the accumulation of fibrinogen and
fibrin on the luminal surface.29,166 Finally, high-porosity
materials (45m) enable fibrovascular infiltration, reduc-
ing the compliance of novel elastic conduits over time and
potentially impairing their performance.97
These limitations in the assessment of endothelializa-
tion in animals are then compounded by the effects of
senescence and location. Although generally referring to
animal maturity, senescence may also refer to the “in vitro
age” of cultured cells. In vitro methods of seeding conduits
with autologous ECs before implantation require expan-
sion of ECs by culture; however, the proliferative and
synthetic capacity of ECs is strongly influenced by the
number of subcultures made (passages), with ECs becom-
ing senescent at approximately passage 10.174
The age of the animal is equally important for endothe-
lialization in vivo, where again older animals demonstrate a
reduced capacity for endothelialization of vascular synthet-
ics, a fact that must be remembered when implants in
senescent models such as canines are compared with the
juvenile models often seen, for example, in calves, sheep,
and swine.29
The importance of implant site has received little atten-
tion but has been investigated in canines. Knitted Dacron
conduits implanted as retropleural (thoracic aorta) interpo-
sition, retroperitoneal (abdominal aorta) interposition, or
subcutaneous (carotid-femoral) bypass grafts were com-
pared after periods of implantation of up to 3 years.182-184
Grafts implanted in the thoracic aorta exhibited firm adher-
ence of perigraft tissues to the conduit exterior and were
associated with rapid formation of a confluent endothelial-
ized lumen within 8 to 16 weeks. Retroperitoneal grafts
exhibited greater variation in healing, with a loosely adher-
ent outer capsule associated with perianastomotic endo-
thelial growth only, whereas firmly encapsulated grafts
demonstrated healing comparable to thoracic grafts. Sub-
cutaneous grafts, however, showed slow and limited endo-
thelialization, with a luminal surface composed mostly of
fibrin despite the formation of a thin well-attached outer
capsule, results similar to those seen in axillofemoral grafts
explanted from humans. These studies highlight the impor-
tance of implant site on graft healing and demonstrate the
need to compare results obtained from similar implant
locations.
Overall, it is clear that animal models for the assessment
of novel conduits using tissue-engineering methods must
take into account not only the variation in healing response
between species but also the strong influence of animal
senescence and anatomic implant location, complicating
the extrapolation of results seen in healthy animals to
diseased humans.Atherosclerosis of tissue-engineered vessels. The
creation of artificial blood vessels incorporating a living
intima and media raises the possibility of synthetic grafts
susceptible to degeneration by atherosclerosis in the same
manner as native vessels. Assessment of these conduits is
therefore enhanced by the use of species able to replicate
the development of this disease as seen in humans.
Atherosclerosis occurs naturally in humans, in some
nonhuman primates (including chimpanzees and various
monkeys), and in pigs, whereas other species such as rabbits
are useful because they are highly responsive to dietary
cholesterol manipulation and develop fatty lesions quickly,
although the lesions themselves are much more fatty and
macrophage-rich. Dogs and rats are not good models be-
cause they require a significant change in diet to produce a
vascular lesion, and ovine models are not used. Guinea pigs
are unique in their striking similarity to humans in terms of
cholesterol and lipoprotein metabolism.42
Nonhuman primates provide an important model due
to their close phylogenetic relationship to humans and
similarities in lipid metabolism and plaque deposition, al-
though the overall severity of lesions seen in primates is less
than that seen in humans. Macaque species, particularly
rhesus and cynomolgus monkeys, are commonly used, and
a genetic strain of baboons has also been developed. Pigs
are another popular model of atherosclerosis due to simi-
larities to humans in terms of diet, cardiovascular system,
lipid metabolism, and development of atheromatous le-
sions, although the use of swine for vascular conduit studies
entails particular difficulties, as previously described.49
Other common models of atherogenesis often use an-
imals genetically altered through inbreeding of a spontane-
ous mutation (eg, Watanabe heritable hyperlipidemic rab-
bit) or as a result of genetic modification, including
insertion of exogenous genes (eg, transgenic rat and rabbit
models) and selective deletion or replacement of endoge-
nous genes (eg, knockout murine models). Although these
modifications render species such as mice susceptible to
atherogenesis, the addition of lipid-enriched Western-type
diets greatly accelerate the rate of lesion development.Mice
deficient in apolipoprotein E (generated by selective inac-
tivation of the apoE gene) are hypercholesterolemic and
spontaneously develop atherosclerotic lesions strikingly
similar to those in humans, even on regular chow. Low-
density lipoprotein receptor-knockout mice exhibit a more
modest lipoprotein abnormality that is greatly increased by
the use of a cholesterol-rich diet. However, although mice
are the most widely used experimental model of atheroscle-
rosis, the use of mice would severely limit the size of
conduit able to be implanted. Transgenic rabbit models
expressing human genes bridge the gap between the labo-
ratory mouse and larger domesticated mammals and are
able to accommodate a variety of conduit sizes, as previ-
ously mentioned.42
In conclusion, the assessment of novel tissue-engi-
neered vascular conduits provides new challenges to animal
modeling and emphasizes the importance of careful con-
JOURNAL OF VASCULAR SURGERY
July 2010190 Byrom et alsideration when selecting an appropriate model. Many
elements influence the performance of vascular grafts,
including:
● species factors, such as coagulation and healing, in-
cluding endothelialization, IH, remodeling, and en-
capsulation;
● host factors, such as senescence and inter-individual
variation in species effects, for example, variable plate-
let aggregation in dogs;
● local factors, including implant location (eg, subcuta-
neous, retroperitoneal) and hydrodynamics (eg, blood
flow, wall shear stress);
● study factors, including duration of implant and selec-
tion of method used (eg, anastomotic technique); and
● conduit factors, including diameter, length, porosity,
and suitability to tissue incorporation.
The relative importance of these individual determi-
nants depends on the study objective and the conduit
material and should be considered in the design of animal
experiments to assess novel vascular conduits.
RECOMMENDATIONS
The following recommendations are given for the de-
sign of future studies that seek to use animal models for the
assessment of novel vascular conduits:
1. Among the commonly available species, sheep are the
large animal of choice for the assessment of vascular
conduits 4 to 6 mm in diameter. Although previously
recommended, the canine demonstrates greater dissimilar-
ities and variability in hemostatic mechanisms as well as a
less stringent test of conduit patency and a propensity for
the rapid endothelialization of vascular prosthetics.
2. Baboons provide the closest approximation for throm-
bogenicity studies for those with access to this species.
In addition, baboons provide an ideal model for the
assessment of tissue-engineered conduits due to the
greater availability of cellular markers, reduced fibrous
encapsulation of foreign implants, and their inherent
susceptibility to atherosclerosis.
3. Rabbits are the small animal of choice for conduits 1 to
4 mm in diameter, enabling bilateral implantation of
longer conduits and having a greater similarity than rats
to humans in coagulation, endothelialization, and pa-
tency. The use of rats for the patency assessment of short
graft segments, especially in the absence of a clinically
relevant control, should be avoided.
4. Implantation of test conduits with a suitable control in
the same animal and in the same position (carotid or
femoral) is recommended. By doing so, the effects of
interindividual variability in thrombogenicity and other
determinants of conduit performance, including animal
senescence and graft location, is reduced.
SUMMARY
The search for the ideal vascular conduit to overcome
the limitations of currently available small-diameter graftsgenerates candidate materials that ultimately require assess-
ment in vivo. The selection of the animal model to be used
is most importantly determined by the validity of the as-
sumption that the model correctly simulates the response
to the prosthesis that would be expected in the clinical
situation. Knowledge of the comparative hematology be-
tween species, the comparative hydrodynamics between
implant locations, and species differences for other deter-
minants of conduit performance such as endothelialization
and anastomotic IH enables the reader or researcher to
assess the validity of this assumption and hence the appli-
cability of results to clinical practice. Recommendations for
the initial assessment of novel vascular conduits designed
for peripheral vascular surgery are for insertion as bilateral
carotid or femoral implants into sheep for conduits 4 to 6
mm in diameter and into rabbits for smaller conduits.
Current interest in the development of tissue-engineered
conduits may result in the greater availability and use of
baboons and other nonhuman primates.
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